-+ 0.00%
-+ 0.00%
-+ 0.00%

*Entero Therapeutics Announces Proposed Reverse Merger With Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company >ENTO

Dow Jones·11/13/2024 12:00:00

Please log in to view news